Chronic heart failure
Conditions
Interventions
Experimental group:Xinyang Pian
Control group:Xinyang tablet mimic medicine
Sponsors
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Have a history of chronic heart failure for more than 3 months or have clinical symptoms of heart failure for more than 3 months. The diagnosis of chronic heart failure should refer to the "2018 Guidelines for the Diagnosis and Treatment of Chronic Heart Failure in China" issued by the Chinese Society of Cardiovascular Medicine. ; 2. Aged 18 to 80 years; 3. Cardiac function class II-IV (NYHA), left ventricular ejection fraction = 450pg/ml; 4. Those who meet the syndrome differentiation criteria of TCM deficiency of qi and yang, blood stasis and water stasis; 5. Those who have received at least 2 weeks of conventional drug therapy with fixed doses of western medicine, and have not been given vasoactive drugs or diuretics for intravenous therapy; 6. Those who have not used traditional Chinese medicine for the treatment of heart failure within 2 weeks before enrollment; 7. Those who participated voluntarily, understood and signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Acute cardiac insufficiency. 2. Those who undergo coronary revascularization and cardiac resynchronization therapy within 12 weeks, or those who plan to undergo cardiac resynchronization therapy within 12 weeks; 3. Accompanied by cardiogenic shock, or fatal arrhythmia, type II or higher sinoatrial or atrioventricular block, obstructive cardiomyopathy, restrictive cardiomyopathy, pulmonary heart disease disease, congenital heart disease, significant hemodynamic changes in patients with unrepaired valvular heart disease, large aneurysm, dissecting aneurysm, constrictive pericarditis, myocarditis, cardiac tamponade, pulmonary embolism, progressively worsening unstable angina or acute Patients with myocardial infarction, and other diseases that affect the efficacy and safety of drugs for heart failure. 4. Combined with severe lung, liver and kidney dysfunction, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, serum creatinine exceeding 2 times the upper limit of normal, serum potassium > 5.5mmol/L; endocrine system, hematopoietic system and other serious factors onset disease. 5. Patients with uncontrolled hypertension, systolic blood pressure >=180/mmHg and/or diastolic blood pressure >=110mmHg; systolic blood pressure <90mmHg and/or diastolic blood pressure <60mmHg; 6. Pregnant or lactating women. 7. Cancer patients, combined with mental illness, or unwilling to cooperate. 8. Participated in clinical investigators of other drugs within 1 month. 9. The researcher believes that it is not suitable to participate in the research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NT-pro BNP;6-minute walking distance; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cardiac function classification;Traditional Chinese Medicine syndrome score;Echocardiography;Minnesota Heart Failure Quality of Life Questionnaire; | — |
Countries
China
Contacts
Public ContactXian Shaoxiang
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Outcome results
None listed